CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK” Livestream Event on April 17, 2020 at 12:30 pm ET / 9:30 am PT Apr 16, 2020 6:00am EDT
CytoDyn’s Phase 2 Basket Trial for 22 Solid Cancer Tumors Treats First Patient with Leronlimab; Patient Enrollment Delayed Due to COVID-19 Apr 15, 2020 6:00am EDT
Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged Apr 13, 2020 6:15am EDT
CytoDyn Appoints Scott A. Kelly, M.D., as Chief Medical Officer and Head of Business Development Apr 13, 2020 6:00am EDT
Blood Samples at Day 0, 3 and 7 for Severely Ill COVID-19 Patients Clearly Indicate Leronlimab Has Significantly Reduced the Cytokine Storm in All (7) Patients and All Patients Demonstrated Immunological Benefit at Both Day 3 and Day 7 Apr 09, 2020 6:15am EDT
Severely Ill COVID-19 Patient at Leading Southern California Medical Center Extubated Three Days After Treatment with CytoDyn’s Leronlimab; Two Moderate COVID-19 Patients Removed from External Oxygen Following One Day of Treatment with Leronlimab and Discharged from Hospital Apr 09, 2020 6:00am EDT
CytoDyn Collaborating with U.K.’s Department of Health to Provide Emergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients Apr 07, 2020 6:00am EDT
First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated Apr 06, 2020 6:00am EDT
